Cargando…
Course of Fecal Calprotectin after mRNA SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Diseases
Background: Two years into the pandemic, vaccination remains the most effective option to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Preliminary studies suggest vaccination efficacy in patients with inflammatory bowel diseases...
Autores principales: | Pokryszka, Jagoda, Wagner, Angelika, Wiedermann, Ursula, Tobudic, Selma, Herkner, Harald, Winkler, Stefan, Brehovsky, Sonja, Reinisch, Walter, Novacek, Gottfried |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146449/ https://www.ncbi.nlm.nih.gov/pubmed/35632515 http://dx.doi.org/10.3390/vaccines10050759 |
Ejemplares similares
-
SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients – A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel Disease
por: Wagner, Angelika, et al.
Publicado: (2022) -
Fecal calprotectin in inflammatory bowel disease
por: Walsham, Natalie E, et al.
Publicado: (2016) -
The Role of Fecal Calprotectin in Investigating Inflammatory Bowel Diseases
por: Erbayrak, Mustafa, et al.
Publicado: (2009) -
Fecal Calprotectin for the Diagnosis and Management of Inflammatory Bowel Diseases
por: Kapel, Nathalie, et al.
Publicado: (2023) -
The usefulness of fecal calprotectin in assessing inflammatory bowel disease activity
por: Lee, Yang Woon, et al.
Publicado: (2019)